Kesmalea Therapeutics
Biotechnology Research in United Kingdom
Overview
Kesmalea is developing a pipeline of novel therapeutics founded on the ability to transform large protein degraders into small molecules. This is achieved through SELFTAC®, a platform designed to combine the power of protein degradation with advantages such as oral bioavailability and central nervous system (CNS) penetration, among other attributes. Kesmalea’s current research spans targets in oncology and diseases of the CNS, with broader applicability. The company is built on foundational scientific work by founder & CSO Harry Finch, Ph.D., a noted medicinal chemist and entrepreneur.
Tagline
Transforming protein degradation to create new medicines: A new class of oral, CNS penetrant protein degraders.
EMPLOYEES
11-50 employees
FOUNDED
—
HQ
London
TYPE
Privately Held
Location
- Street
- —
- City
- London
- Region
- —
- Postal code
- —
- Country
- United Kingdom
Email patterns
See email patterns for Kesmalea Therapeutics
Address formats, how often each is used and the mail provider.
Start for freeTrade fairs
FAQ
What is the company name?
kesmalea.com is the website of Kesmalea Therapeutics.
What is the industry of the company?
Kesmalea Therapeutics (kesmalea.com) is in the Biotechnology Research industry.
How many employees does the company have?
Kesmalea Therapeutics (kesmalea.com) has 11-50 employees.
What is the company type?
The company type of Kesmalea Therapeutics (kesmalea.com) is Privately Held.
Where is the company headquartered?
Kesmalea Therapeutics (kesmalea.com) is headquartered in London.
What is the address of the company?
The address of Kesmalea Therapeutics (kesmalea.com) is London, United Kingdom.
What are the social media accounts of the company?
The social media account of Kesmalea Therapeutics (kesmalea.com) is LinkedIn.
Social media